About Glint Pharmaceuticals
Glint has developed a novel, patented approach for extended drug delivery by the incorporation of vitamin E (α tocopherol) into standard silicon hydrogel polymer contact lenses. The Glint lens provides a new, non-surgical method to treat eye disease, increasing patient compliance while delivering appropriate drug to the eye. Improving drug delivery efficiency to the ocular tissue may help reduce the incidence of serious ocular complications and blindness. Sustained release will eliminate the need for multiple drops each day. Corneal injury from trauma, infection, or surgery affects over 8,000,000 people per year in the US and Europe with blindness occurring in a significant number of cases.